State Street Corp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 1.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,881,362 shares of the biopharmaceutical company’s stock after buying an additional 46,674 shares during the quarter. State Street Corp owned about 4.72% of Regeneron Pharmaceuticals worth $3,701,390,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the company. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $26,000. Armstrong Advisory Group Inc. boosted its position in Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 28 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. Trust Co. of Vermont acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. Finally, Fiduciary Financial Advisors acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. 83.31% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In related news, EVP Joseph J. Larosa sold 4,466 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the sale, the executive vice president directly owned 38,906 shares of the company’s stock, valued at approximately $37,563,353.94. This represents a 10.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Huda Y. Zoghbi sold 7,439 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total transaction of $7,219,251.94. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,652,693.38. This represents a 81.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 32,039 shares of company stock worth $29,825,285. 6.97% of the stock is currently owned by corporate insiders.
Regeneron Pharmaceuticals Stock Down 0.3%
Shares of REGN stock opened at $920.69 on Friday. The stock has a 50 day moving average of $829.76 and a 200 day moving average of $752.07. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $95.25 billion, a P/E ratio of 20.33, a P/E/G ratio of 1.22 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. During the same period in the previous year, the company posted $11.83 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 36.3% on a year-over-year basis. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.30%.
Analysts Set New Price Targets
A number of equities analysts have issued reports on REGN shares. Wells Fargo & Company raised their price target on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the stock an “equal weight” rating in a research report on Monday, November 2nd. Weiss Ratings upgraded shares of Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, November 2nd. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Leerink Partners raised their target price on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the stock a “market perform” rating in a report on Monday, November 2nd. Finally, Evercore boosted their target price on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $904.41.
Get Our Latest Stock Report on Regeneron Pharmaceuticals
Latest Regeneron Pharmaceuticals News
Here’s some of the latest news about REGN:
- Positive Sentiment: The European Commission approved more flexible Libtayo dosing across six cancer indications. The change could improve convenience for patients and support Regeneron’s oncology business. Libtayo dosing flexibility approval
- Positive Sentiment: Regeneron plans to present new hematology data at the December ASH meeting, including potentially pivotal Ordspono results in marginal zone lymphoma. The data could provide further evidence of the company’s pipeline opportunity, though it is not yet a clinical or regulatory outcome. Regeneron ASH data announcement
- Neutral Sentiment: Livsayis will compete with established treatments for generalized myasthenia gravis, so adoption and commercial performance remain important to watch despite its distinctive dosing schedule. Livsayis competitive context
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
